# A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis

> **NCT00993317** · PHASE3 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 127 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo of CDP870
- **DRUG:** CDP870 200mg
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00993317
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2012-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993317, "A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00993317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*